A phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma

被引：48
|
作者：
Bedano, P. M.
Perkins, S.
Burns, M.
Kessler, K.
Nelson, R.
Schneider, B. P.
Risley, L.
Dropcho, S.
Loehrer, P. J.
机构：
[1] Community Reg Canc Care, Indianapolis, IN USA
[2] Indiana Univ Sch Med, Indianapolis, IN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.19087
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
19087
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase II trial of pemetrexed in patients with recurrent thymoma or thymic carcinoma.
    Loehrer, P. J., Sr.
    Yiannoutsos, C. T.
    Dropcho, S.
    Burns, M.
    Helft, P.
    Chiorean, E. G.
    Nelson, R. P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 383S - 383S
  • [2] A Phase II Study of Pemetrexed in Patients with Recurrent Thymoma and Thymic Carcinoma
    Gbolahan, Olumide B.
    Porter, Ryan F.
    Salter, John T.
    Yiannoutsos, Constantin
    Burns, Matthew
    Chiorean, E. Gabriella
    Loehrer, Patrick. J.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (12) : 1940 - 1948
  • [3] Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma
    Sathornsumetee, Sith
    Desjardins, Annick
    Vredenburgh, James J.
    McLendon, Roger E.
    Marcello, Jennifer
    Herndon, James E.
    Mathe, Alyssa
    Hamilton, Marta
    Rich, Jeremy N.
    Norfleet, Julie A.
    Gururangan, Sridharan
    Friedman, Henry S.
    Reardon, David A.
    [J]. NEURO-ONCOLOGY, 2010, 12 (12) : 1300 - 1310
  • [4] Phase II trial of bevacizumab plus erlotinib for patients with recurrent malignant gliomas: Final results.
    Sathornsumetee, S.
    Desjardins, A.
    Vredenburgh, J. J.
    McLendon, R. E.
    Marcello, J.
    Herndon, J. E.
    Norfleet, J.
    Gururangan, S.
    Friedman, H. S.
    Reardon, D. A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [5] BEVACIZUMAB PLUS ERLOTINIB IN RECURRENT HIGH-GRADE GLIOMA: A PHASE II TRIAL
    Sathornsumetee, Sith
    Desjardins, Annick
    Vredenburgh, James J.
    Rich, Jeremy N.
    Gururangan, Sridharan
    Janney, D. E.
    Friedman, Allan H.
    Friedman, Henry S.
    Reardon, David A.
    [J]. NEURO-ONCOLOGY, 2009, 11 (06) : 906 - 906
  • [6] Phase II trial of capecitabine, oxaliplatin plus bevacizumab followed by bevacizumab plus erlotinib: XELOBER trial
    Munoz, A.
    Salut, A.
    Pericay, C.
    Garcia, C.
    Roca, J.
    Duenas, R.
    Rivera, F.
    Alonso, V.
    Alonso, M.
    Falco, E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [7] A phase II clinical trial of selinexor in patients with advanced thymoma and thymic carcinoma
    Aggarwal, Vanya
    Tang, Tianzhi
    Daugaard, Gedske
    Liu, Stephen V.
    Ahn, Jaeil
    Besse, Benjamin
    Girard, Nicolas
    Giaccone, Giuseppe
    Kim, Chul
    Petersen, Peter
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] Phase II study of bevacizumab plus erlotinib for recurrent malignant gliomas
    Sathornsumetee, S.
    Desjardins, A.
    Vredenburgh, J. J.
    Rich, J. N.
    Gururangan, S.
    Friedman, A. H.
    Friedman, H. S.
    Reardon, D. A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [9] Phase II trial of bevacizumab and erlotinib in patients with metastatic renal carcinoma (RCC)
    Hainsworth, JD
    Sosman, JA
    Spigel, DR
    Schwert, RC
    Carrell, DL
    Hubbard, F
    Greco, FA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 382S - 382S
  • [10] Phase II trial of bevacizumab and erlotinib in recurrent glioblastoma multiforme (GBM)
    Sathornsumetee, Sith
    Vredenburgh, James
    Rich, Jeremy
    Desjardins, Annick
    Quinn, Jennifer
    Bota, Daniela
    Goli, Krishna
    Mathe, Alyssa
    Gururangan, Sridharan
    Friedman, Allan
    Friedman, Henry
    Reardon, David
    [J]. NEURO-ONCOLOGY, 2007, 9 (04) : 516 - 516
12345